对转移性割抵抗性前列腺癌的一线全身治疗的比较有效性:系统性审查和网络元分析
Jiahuan Ai1, Liuying Jian1, Xiaoqin Wen1
1College of Pharmacy/Southern Institute of Pharmacoeconomics and Health Technology Assessment, Jinan University, Guangzhou, 510632, China.
概括
塔拉佐巴里布加恩扎胺在一线转移性割抵抗性前列腺癌中显示出优异的无进展生存率. 这种组合可能是整体和HRRm种群的首选治疗方法.
科学领域:
- 在瘤学瘤学.
- 临床药理学 临床药理学
- 生物统计学 生物统计学
背景情况:
- 转移性割抵抗性前列腺癌 (mCRPC) 缺乏对比的试验,比较多ADP-ribose聚合酶抑制剂 (PARPi) 和雄激素受体信号抑制剂 (ARSi).
- 评估一线全身治疗mCRPC的比较有效性对于优化患者的治疗结果至关重要.
研究的目的:
- 进行系统审查和网络元分析.
- 评估和比较mCRPC各种全身治疗药物的有效性.
主要方法:
- 全面的文献搜索到2023年4月.
- 网络元分析评估无放射性进展生存率 (rPFS) 和整体生存率 (OS).
- 贝叶斯框架具有固定效应模型和受限制的平均存活时间 (RMST) 分析强度.
主要成果:
- 九项研究 (6,830名患者) 评估了8种治疗选择.
- 在整体和HRRm种群中,Talazoparib + enzalutamide (TALA + ENZA) 显示出优异的rPFS.
- 在贝叶斯和RMST模型之间观察到一致的疗效等级;TALA + ENZA通过RMST显示了最高的3年OS益处.
结论:
- 塔拉佐巴里布 + 恩扎胺是mCRPC患者,包括HRRm的首选第一线治疗方法.
- 由于网络元分析的局限性和建模假设,应谨慎解释结果.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
01:20Comparing the Survival Analysis of Two or More Groups
177
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
177
01:21Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345